- Home
- MYGN vs AURA Comparison
MYGN vs AURA Comparison
Compare MYGN & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- AURA
- Stock Information
- Founded
- MYGN 1991
- AURA 2007
- Country
- MYGN United States
- AURA United States
- Employees
- MYGN N/A
- AURA N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- AURA Health Care
- Exchange
- MYGN Nasdaq
- AURA Nasdaq
- Market Cap
- MYGN 423.1M
- AURA 396.8M
- IPO Year
- MYGN 1995
- AURA 2021
- Fundamental
- Price
- MYGN $3.91
- AURA $6.74
- Analyst Decision
- MYGN Hold
- AURA Strong Buy
- Analyst Count
- MYGN 15
- AURA 6
- Target Price
- MYGN $15.14
- AURA $22.33
- AVG Volume (30 Days)
- MYGN 1.3M
- AURA 157.8K
- Earning Date
- MYGN 08-12-2025
- AURA 08-11-2025
- Dividend Yield
- MYGN N/A
- AURA N/A
- EPS Growth
- MYGN N/A
- AURA N/A
- EPS
- MYGN N/A
- AURA N/A
- Revenue
- MYGN $831,300,000.00
- AURA N/A
- Revenue This Year
- MYGN N/A
- AURA N/A
- Revenue Next Year
- MYGN $6.64
- AURA N/A
- P/E Ratio
- MYGN N/A
- AURA N/A
- Revenue Growth
- MYGN 7.38
- AURA N/A
- 52 Week Low
- MYGN $3.78
- AURA $4.35
- 52 Week High
- MYGN $29.30
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- MYGN 30.48
- AURA 51.10
- Support Level
- MYGN $4.43
- AURA $6.38
- Resistance Level
- MYGN $4.83
- AURA $7.48
- Average True Range (ATR)
- MYGN 0.25
- AURA 0.39
- MACD
- MYGN -0.10
- AURA -0.03
- Stochastic Oscillator
- MYGN 9.32
- AURA 32.73
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.